Category: Latest News
-
Greenwich LifeSciences Shares Jump on Early Breast Cancer Trial Readout
Shares of Greenwich LifeSciences (NASDAQ:GLSI) soared about 37% after the clinical-stage biotech released early data from its FLAMINGO-01 study indicating a sharp drop in breast cancer recurrence rates. The company said preliminary analysis from the open-label, non-HLA-A02 arm of the trial — which includes 250 patients — showed an estimated reduction in recurrence of roughly…
-
Zillow Shares Slide After Google Trials New Property Advertising Tool
Zillow Group Inc. (NASDAQ:ZG) shares dropped more than 5.5% on Monday after reports that Google is piloting a new real estate advertising format that could eventually encroach on Zillow’s core business. Google has begun testing a mobile-focused property ad experience that places detailed real estate listings directly within search results. The format includes property information,…
-
Adaptive Biotechnologies Enters Two TCR Licensing Agreements With Pfizer
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has entered into two separate agreements with Pfizer Inc. (NYSE:PFE) that will see the companies collaborate on T-cell receptor (TCR) research to support drug discovery and development. The first deal focuses on rheumatoid arthritis, with Adaptive deploying its immune medicine platform to identify T-cell receptors linked to disease activity. Using Pfizer’s…
-
FibroGen Shares Advance After Roxadustat Earns Orphan Drug Status
Shares of FibroGen, Inc. (NASDAQ:FGEN) climbed about 3% on Monday after the company said its drug candidate roxadustat has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of myelodysplastic syndromes (MDS). The designation was awarded by the FDA’s Office of Orphan Products Development and comes with several potential…
-
Kyverna Shares Jump on Strong Results From SPS Clinical Trial
Kyverna Therapeutics (NASDAQ:KYTX) shares climbed 14% on Monday after the company reported encouraging topline outcomes from its registrational Phase 2 KYSA-8 study evaluating mivocabtagene autoleucel (miv-cel) in patients with stiff person syndrome (SPS). The clinical-stage biotech said the CAR T-cell therapy delivered statistically significant benefits across all primary and secondary endpoints. Patients treated with miv-cel…
-
Milestone Pharmaceuticals Shares Rally After FDA Greenlights First At-Home PSVT Nasal Therapy
Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved CARDAMYST, the first nasal spray that patients can self-administer to treat paroxysmal supraventricular tachycardia (PSVT). The decision introduces the first new treatment option in more than three decades for the estimated 2 million people in the U.S. affected by PSVT,…
-
Immunome Shares Jump on Strong Phase 3 Data for Desmoid Tumor Therapy
Immunome (NASDAQ:IMNM) shares soared about 30% after the biotech group reported encouraging topline findings from its Phase 3 RINGSIDE study evaluating varegacestat in patients with desmoid tumors. The pivotal trial achieved its primary endpoint, showing a statistically meaningful improvement in progression-free survival versus placebo. Results indicated an 84% reduction in the risk of disease progression…
-
ServiceNow Shares Slide on Reports of Possible $7bn Armis Acquisition
Shares in ServiceNow (NYSE:NOW) moved lower in pre-market trading on Monday after reports emerged that the company is holding advanced discussions to buy cybersecurity firm Armis in a deal that could be valued at as much as $7 billion. According to a Bloomberg News report citing people familiar with the situation, an announcement could come…
-
In the chair with bp’s Craig Marshall: From bp’s biggest find in 25 years to value creation
In this interview, Craig Marshall, head of investor relations at bp (NYSE:BP), provides investors with a comprehensive update on the company’s strategic transformation and operational momentum. Following bp’s February 2025 strategy update, Craig addresses the disciplined capital reallocation, with oil and gas investment up 20% and transition spending down 70%. He also outlines management’s ambitious targets…
-
Google Secures Solar Power Supply in Malaysia, Report Says
Google, part of Alphabet (NASDAQ:GOOGL), has reached an agreement to source solar energy in Malaysia, advancing its strategy to power global operations with clean electricity, according to a Bloomberg report published Monday. The deal involves Google purchasing power from a 30-megawatt solar facility in the state of Kedah. The project is being developed by a…